Literature DB >> 2139891

The adenovirus EII early promoter has multiple EIA-sensitive elements, two of which function cooperatively in basal and virus-induced transcription.

C F Manohar1, J Kratochvil, B Thimmapaya.   

Abstract

The mechanism by which the adenovirus-encoded nuclear oncogene EIA activates transcription of several viral and host promoters is an important issue in the regulation of eucaryotic gene expression and virus-host cell interactions. Identification of cis-acting elements of the promoters and the cognate host transcription factors that are targets for EIA action is crucial for our understanding of the EIA-mediated control of coordinately regulated genes. The adenovirus EII early promoter has a complex architecture and contains two overlapping promoters with start sites at +1 (major promoter) and -26 (minor promoter). The major promoter responds strongly to virus-encoded trans activators EIA and EIV and contains four elements: a TAGA motif analogous to the TATA box, two EIIF sites present in an inverted orientation, and an ATF/CREB site. To determine precisely the roles played by these cis-acting elements in both basal and virus-induced transcription when the promoter is situated in its natural context, we investigated the phenotype of a series of linker scan promoter substitution mutants inserted into the viral chromosome. Promoter constructs harboring linker scan mutations in each element were rebuilt into a novel EIA- adenovirus vector, and transcriptional activity was monitored in virus-infected cells. In the absence of virus-encoded trans activators, basal activity in vivo was dependent on all four cis-acting elements. Surprisingly, a promoter mutant with only one of the two EIIF sites intact could not promote transcription in vivo, suggesting that the two EIIF sites function cooperatively even in basal transcription. Promoters harboring mutations in either of these two EIIF sites also failed to bind to an infection-specific form of EIIF in gel shift assays and competed only very weakly for EIIF binding with the wild-type promoter fragment. The dramatic cooperativity shown by the two inverted EIIF sites of the EII promoter both in vivo and in vitro could reflect simultaneous contact of both sites by the transcription factor EIIF. Furthermore, promoter mutants with mutations in the TAGA motif, the two EIIF sites, and the single ATF site all failed to respond to virus-encoded trans activators. Whereas recent results demonstrate that EIIF activity can be modulated independently by EIV, leading to transactivation of this promoter, our results and those published previously strongly indicate that the three different transcription factors that bind to TAGA, EIIF, and ATF motifs of the EII early promoter are all targets for EIA regulation in vivo. Thus, strong transactivation of the EII early promoter through these multiple EIA-sensitive elements and independently by the recently discovered EIV pathway suggests that the EII early promoter is stringently regulated in virus-infected cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Mesh:

Substances:

Year:  1990        PMID: 2139891      PMCID: PMC249420     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Organization of the transcriptional control region of the E1b gene of adenovirus type 5.

Authors:  C L Parks; S Banerjee; D J Spector
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  The abundance and in vitro DNA binding of three cellular proteins interacting with the adenovirus EIIa early promoter are not modified by the EIa gene products.

Authors:  P Jalinot; B Devaux; C Kédinger
Journal:  Mol Cell Biol       Date:  1987-10       Impact factor: 4.272

3.  Role of an adenovirus E2 promoter binding factor in E1A-mediated coordinate gene control.

Authors:  I Kovesdi; R Reichel; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

4.  A cellular protein, activating transcription factor, activates transcription of multiple E1A-inducible adenovirus early promoters.

Authors:  K A Lee; T Y Hai; L SivaRaman; B Thimmappaya; H C Hurst; N C Jones; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  Two promoter-specific host factors interact with adjacent sequences in an EIA-inducible adenovirus promoter.

Authors:  L SivaRaman; B Thimmappaya
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

6.  Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene.

Authors:  M R Montminy; L M Bilezikjian
Journal:  Nature       Date:  1987 Jul 9-15       Impact factor: 49.962

7.  Upstream regulatory regions required to stabilize binding to the TATA sequence in an adenovirus early promoter.

Authors:  J Garcia; F Wu; R Gaynor
Journal:  Nucleic Acids Res       Date:  1987-10-26       Impact factor: 16.971

8.  A cellular transcription factor E4F1 interacts with an E1a-inducible enhancer and mediates constitutive enhancer function in vitro.

Authors:  K A Lee; M R Green
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

9.  In vivo identification of multiple promoter domains of adenovirus EIIA-late promoter.

Authors:  G Bhat; L SivaRaman; S Murthy; P Domer; B Thimmappaya
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

10.  Promoter interaction of the E1A-inducible factor E2F and its potential role in the formation of a multi-component complex.

Authors:  A S Yee; R Reichel; I Kovesdi; J R Nevins
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

View more
  11 in total

1.  The C-terminal 70 amino acids of the adenovirus E4-ORF6/7 protein are essential and sufficient for E2F complex formation.

Authors:  R J O'Connor; P Hearing
Journal:  Nucleic Acids Res       Date:  1991-12-11       Impact factor: 16.971

2.  E1A 12S and 13S of the transformation-defective adenovirus type 12 strain CS-1 inactivate proteins of the RB family, permitting transactivation of the E2F-dependent promoter.

Authors:  B M Pützer; H Rumpf; S Rega; D Brockmann; H Esche
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  The adenovirus E4-6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex.

Authors:  S Obert; R J O'Connor; S Schmid; P Hearing
Journal:  Mol Cell Biol       Date:  1994-02       Impact factor: 4.272

4.  Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1.

Authors:  R J O'Connor; P Hearing
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

5.  The E4-6/7 protein functionally compensates for the loss of E1A expression in adenovirus infection.

Authors:  R J O'Connor; P Hearing
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Activation of a dual adenovirus promoter containing nonconsensus TATA motifs in Schizosaccharomyces pombe: role of TATA sequences in the efficiency of transcription.

Authors:  S Swaminathan; P Malhotra; C F Manohar; R Dhar; B Thimmapaya
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

7.  Simian virus 40 small-t does not transactivate RNA polymerase II promoters in virus infections.

Authors:  P Rajan; V Dhamankar; K Rundell; B Thimmapaya
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

8.  Simian virus 40 small t antigen trans activates the adenovirus E2A promoter by using mechanisms distinct from those used by adenovirus E1A.

Authors:  M R Loeken
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Specific transcription from the adenovirus E2E promoter by RNA polymerase III requires a subpopulation of TFIID.

Authors:  R Pruzan; P K Chatterjee; S J Flint
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

10.  Effects of mutation of the CREB binding site of the somatostatin promoter on cyclic AMP responsiveness in CV-1 cells.

Authors:  M R Loeken
Journal:  Gene Expr       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.